A miRNA-Driven Inference Model to Construct Potential Drug-Disease Associations for Drug Repositioning

Table 5

Prediction results of associated diseases for the drug docetaxel.

Drug	Common miRNA(s)	Disease	P value	Evidence
Docetaxel	hsa-miR-100; hsa-miR-200b; hsa-miR-99b	Endometriosis	0.00629	CTD confirmed
Docetaxel	hsa-miR-100; hsa-miR-200b; hsa-miR-502; hsa-miR-99b	Ovarian neoplasms	0.00850	CTD confirmed
Docetaxel	hsa-miR-100; hsa-miR-200b; hsa-miR-99b	Prostatic neoplasms	0.0423	CTD confirmed
Docetaxel	hsa-miR-99b	Sarcoma, synovial	0.0260	CTD confirmed
Docetaxel	hsa-miR-100; hsa-miR-200b; hsa-miR-99b	Urinary bladder neoplasms	0.0154	CTD confirmed
Docetaxel	hsa-miR-100; hsa-miR-200b	Adrenal cortex neoplasms	0.00182	CTD confirmed
Docetaxel	hsa-miR-100; hsa-miR-99b	Atherosclerosis	0.0129	CTD confirmed
Docetaxel	hsa-miR-100; hsa-miR-502	Muscular dystrophies	0.00290	CTD confirmed
Docetaxel	hsa-miR-200b	Glomerulonephritis, IGA	0.0430	CTD confirmed
Docetaxel	hsa-miR-200b	Tongue neoplasms	0.0260	CTD confirmed
Docetaxel	hsa-miR-200b	Diabetic retinopathy	0.00873	CTD confirmed